The clinical trials of HDAC inhibitors for the treatment of castration-resistant prostate cancer diseases were recently reviewed, and only the main outcomes are summarized in Table 1 and Figure 1[24,31]. This evidence concerns the gene HDAC9 and prostate cancer.